Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

628

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Omalizumab
DRUG: Placebo
DRUG: Fluticasone

Sponsor

Novartis Pharmaceuticals